Welcome to Agri Investment Fund

News

18.09.18
ViroVet receives grant from VLAIO (Flanders) to boost the development of its disruptive vaccine technology

ViroVet nv announced today that it has received a 590.000 euro grant from Flanderes Innovation & Entrepreneurship (VLAIO) to assess the potential of its PLLAV-vaccination technology in poultry and large ruminants.ViroVet is a leading Belgian biopharmaceutical company active in the development of antiviral drugs and innovative vaccines for use in livestock.  Since its capital increase in December 2016 ViroVet started developing novel and innovative vaccines, termed PLLAV vaccines for Plasmid-Launched Live-Attenuated

16.06.17
Aphea.Bio aims at leading position in next generation agricultural biologicals

New VIB spin-off launches with 9 million euros in funding

10.01.17
ViroVet succesfully raises € 5 million in series A funding

Animal health company focussed on combatting viral infections in livestock

26.09.16
Le Groupe Veviba reprend l'abattoir Adriaens (Velzeke)

Le Groupe Veviba a conclu avec Covavee et Agri Investment Fund (AIF), les actionnaires des Etablissements Adriaens, un accord au terme duquel le groupe Veviba acquiert la totalité des actions des établissements Adriaens.

Veviba et Adriaens sont actifs dans l'abattage et la transformation du bétail bovin.  Grâce à cette opération, ils ont pour objectif de renforcer leur position dans le secteur de la viande bovine et de poursuivre le développement de leur "core-business".

22.09.16
AgroSavfe raises € 7.8 million in a series B financing

AgroSavfe nv, a Belgium-based agro-biotech company, announced today it closed a series B financing round of € 7.8 million.  The funds will be used for the advanced development of its novel Agrobodies® as biopesticides.  The first submissions for regulatory approval in Europe and the US are expected in 2018.

Previous Pause Next